AC Immune is a double-blind placebo controlled study, investigating a novel antibody as a potential therapeutic vaccine against excess tau formation in the brain Title: A Phase Ib/IIa multicenter, double blind, randomized, placebo-controlled study to evaluate the safety, tolerability and immunogenicity of different doses, regimens and combinations of Tau targeted vaccines in subjects with early Alzheimer’s Disease Study Number: ACI-35-1802 Short title: AC Immune Study Sponsor: AC Immune, Switzerland Chief Investigator: Prof Philip Scheltens, Amsterdam UMC Edinburgh PI: Prof Craig Ritchie, University of Edinburgh Ethics ref: Funder: AC Immune Dates (estimated): July 2019 - October 2023 Synopsis: AC Immune is a clinical trial of the ACI-35 drug, which attempts to vaccinate against the abnormal build up of Tau in the brain. Along with amyloid-beta plaques, abnormal levels of Tau, which can disrupt the normal communication of cells, are a hallmark of Alzheimer’s disease. ACI-35 attempts to generate antibodies which target the abnormal Tau in the human brain. The study is a double-blind, placebo controlled study, of 50-75 years of age (male and female) with a diagnosis of mild AD or MCI due to AD. Aims: To assess the safety, tolerability, and immunogenicity of Tau vaccine Recruiting: No. Links and Publications: AC Immune website with further study details. Press release from the CTAD conference in Nov 2021. The video describes Tau and its relationship to Alzheimier's disease. Note that this video is prodcued by Alzheimer's Research Uk and is available on YouTube. Alzheimer's Research UK are not associated with the AC Immune study. This article was published on 2024-08-27
